Center Laboratories, Inc.

4123

TW0004123005

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
43.45 ^TWD	-0.34%		+2.24%	-1.92%

Apr. 22	Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023	CI
Mar. 19	Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Center Laboratories, Inc. Proposes Dividend Distribution for the Year 2021

March 22, 2022 at 05:58 am EDT

The Board of Directors of Center Laboratories, Inc. proposed dividend distribution for the year 2021. Appropriations of earnings in cash dividends to shareholders (TWD per share): 2.5. Total amount of cash dividends to shareholders (TWD): 1,262,621,868.

Latest news about Center Laboratories, Inc.

Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023	Apr. 21	CI
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd	Mar. 12	CI
Center Laboratories, Inc. Announces Wang, Su-Chi Holds Concurrent Position as Chief Investment Officer and Chief Operating Officer	Feb. 06	CI
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023	23-08-11	CI
Center Laboratories, Inc. announced a financing transaction	23-06-19	CI
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Center Laboratories, Inc. Proposes Cash Dividend for the Period from January 1, 2022 to December 31, 2022	23-04-20	CI
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Center Laboratories, Inc. Announces Executive Appointments	22-12-08	CI
Center Laboratories, Inc. Announces Management Changes	22-11-30	CI
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Bao Pharma announced that it has received $100 million in funding from Shenzhen Oriental Fortune Capital Co., Ltd., Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.	22-08-24	CI
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021	22-08-11	CI
Mycenax Biotech Inc. announced that it expects to receive TWD 1.659112761 billion in funding from JCR Pharmaceuticals Co., Ltd., Center Laboratories, Inc.	22-07-26	CI
TOT BIOPHARM International Company Limited announced that it expects to receive HKD 110 million in funding from Center Laboratories, Inc.	22-05-30	CI
Center Laboratories, Inc. Elects Directors	22-05-20	CI
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Center Laboratories, Inc. Proposes Dividend Distribution for the Year 2021	22-03-22	CI
HongKong Jingang Trade Holding Company Limited completed the acquisition of 30.89% stake in Ausnutria Dairy Corporation Ltd from Citagri Easter Ltd, Bioengine Capital Inc., Center Laboratories, Inc. and Bartle van der Meer.	22-01-27	CI
TOT Biopharm Sells 1 Million Shares in Lumosa Therapeutics to Center Laboratories	21-12-08	MT

Chart Center Laboratories, Inc.

Duration

Period

More charts

Company Profile

Center Laboratories, Inc. is a Taiwan-based company principally engaged in the production, marketing and distribution of infant nutrition products, as well as the research and development, processing, production, packaging, marketing and sales of dairy products. The Company's main products include dairy products and probiotic products. The Company is also involved in the manufacture, wholesale and retail of western medicines. The Company distributes its products in the domestic market and to overseas markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CENTER LABORATORIES, INC.	-1.92%	923M
ELI LILLY AND COMPANY	+26.12%	681B
NOVO NORDISK A/S	+21.14%	556B
JOHNSON & JOHNSON	-5.03%	361B
MERCK & CO., INC.	+17.38%	325B
ABBVIE INC.	+5.15%	285B
ASTRAZENECA PLC	+14.09%	235B
NOVARTIS AG	+4.23%	199B
ROCHE HOLDING AG	-11.37%	189B
PFIZER, INC.	-3.75%	157B